- Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024
- Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates
- Fractyl Health Presents Clinical Update on Revita® German Real-World Registry for Patients With Advanced Type 2 Diabetes (T2D)
- Fractyl Health to Present at BofA Securities 2024 Health Care Conference
- Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024
- Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual Meeting
- Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes
- Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs
- UPDATE -- Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity
More ▼
Key statistics
As of last trade, Fractyl Health Inc (GUTS:NMQ) traded at 7.53, 30.87% above the 52 week low of 5.75 set on Apr 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 7.79 |
---|---|
High | 7.79 |
Low | 7.48 |
Bid | 7.47 |
Offer | 7.57 |
Previous close | 7.62 |
Average volume | 174.79k |
---|---|
Shares outstanding | 47.90m |
Free float | 45.81m |
P/E (TTM) | -- |
Market cap | 364.97m USD |
EPS (TTM) | -1.73 USD |
Data delayed at least 15 minutes, as of May 23 2024 15:19 BST.
More ▼